| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763454 | PFIZER | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt |
Jun, 2015
(8 years ago) | |
| US6187341 | PFIZER | Trovafloxacin mesylate tablet |
Jan, 2019
(5 years ago) | |
Trovan is owned by Pfizer.
Trovan contains Trovafloxacin Mesylate.
Trovan has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Trovan are:
- US5763454
- US6187341
Trovan was authorised for market use on 18 December, 1997.
Trovan is available in tablet;oral dosage forms.
Trovan can be used as method of treating bacterial infections.
The generics of Trovan are possible to be released after 20 January, 2019.
Drugs and Companies using TROVAFLOXACIN MESYLATE ingredient
Market Authorisation Date: 18 December, 1997
Treatment: Method of treating bacterial infections
Dosage: TABLET;ORAL
More Information on Dosage
TROVAN family patents
